How immune cells damage and affect nerve fibers in multiple sclerosis
Mechanisms underlying regulation of injured axons in CNS autoimmunity
This work explores whether a specific potassium channel in immune cells and nerve cells causes nerve damage in people with multiple sclerosis and whether blocking it helps explain the effects of the drug 4‑AP.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11235165 on NIH RePORTER |
What this research studies
Researchers use a mouse model that mimics MS and lab-grown immune and nerve cells to study a potassium channel called Kv3 that is found in both T cells and neurons. They compare normal mice with mice engineered to lack Kv3, apply genetic knockdown in cells, and use imaging, flow cytometry, and drug (4‑AP) tests to track how T cells cause axon injury. The team will measure T cell activation, axonal conduction, and nerve damage to see whether blocking Kv3 reduces immune-driven injury. The goal is to reveal mechanisms that could point to ways to protect or repair nerve fibers in people with MS.
Who could benefit from this research
Good fit: People with multiple sclerosis—especially those with inflammatory demyelinating disease or walking difficulties and an interest in treatments that protect nerve fibers—would be the most relevant group.
Not a fit: People with non-inflammatory neurodegenerative conditions or symptoms not driven by immune-mediated axonal injury are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this research could point to a new target (Kv3) or improved use of 4‑AP to protect nerve fibers and slow or prevent disability in MS.
How similar studies have performed: The symptom-relieving drug 4‑AP is already used to improve walking in MS, but targeting Kv3 to prevent immune-driven axon injury is a newer approach supported so far mainly by preclinical animal and cell studies.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Gu, Chen — Ohio State University
- Study coordinator: Gu, Chen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.